PART I Overview We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline produc...
Q2 FY2026 — expected 2026-08-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-11 | 2025-12-31 | 0001660334-26-000008 | EDGAR | 82K words |
| 2025-03-11 | 2024-12-31 | 0000950170-25-037172 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0000950170-24-022659 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0000950170-23-006118 | EDGAR | — |
| 2022-03-02 | 2021-12-31 | 0000950170-22-002685 | EDGAR | — |
| 2021-03-17 | 2020-12-31 | 0001564590-21-013876 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001564590-20-010832 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001564590-19-006800 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001660334-25-000006 | EDGAR | 22K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107358 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070452 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0000950170-24-120982 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-096669 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058208 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061543 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039375 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019169 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022647 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016660 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008242 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001193125-26-101126 | EDGAR | 6K words |
| 2025-12-30 | 0001193125-25-335824 | EDGAR | — |
| 2025-11-24 | 0001193125-25-292155 | EDGAR | — |
| 2025-11-14 | 0001193125-25-283078 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178954 | EDGAR | — |
| 2025-07-30 | 0001193125-25-169309 | EDGAR | — |
| 2025-07-23 | 0001193125-25-162939 | EDGAR | — |
| 2025-07-01 | 0001193125-25-153471 | EDGAR | — |
| 2025-06-12 | 0001193125-25-139959 | EDGAR | — |
| 2025-06-05 | 0001193125-25-135949 | EDGAR | — |
159 total filings indexed. 129 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001660334 |
| Ticker | VRCA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.verrica.com |
| Listed | 2018-06-15 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report